Business

Mereo Biopharma Group Plc – ADR (NASDAQ: MREO) Gains after Announcing Positive Data from Study

Mereo BioPharma Group plc – ADR (NASDAQ: MREO), which has a market capitalization of $343.14 million, was founded in 2015. Mereo BioPharma Group is a UK-based clinical-stage biopharmaceutical company. It primarily focuses on treatments for oncology and some rare diseases. Last week, the company announced positive Desmosine Biomarker Data and the interim data from the alvelestat study, which was meant for patients suffering from Bronchiolitis Obliterans Syndrome. The condition begins after hematopoietic stem cell transplantation. 

About the study

The new study, titled Phase 1b/2, is conducted by the company as per the Clinical Trial Agreement with National Cancer Institute. A total of 30 patients are to be recruited for the study. In the primary endpoints, the company will define optimal biological dose and safety. Both these are based on neutrophil elastase inhibition, which is to be measured with biomarkers after the study reaches Week 8. 

Positive data from the initial study of alvelestat

The company presented its interim data at the Annual Meeting of 2020 American Society of Hematology. The data focuses on the first seven patients in the company’s open-label study. The company reported that while alvelestat was tolerated well, the Phase 1 study did not reach the maximum-tolerated dose. Meanwhile, analysis of biomarker desmosine elastin breakdown is now complete. Also, the company is presenting biomarker analyses of its first seven patients. Dr. Pavletic is conducting this analysis along with the team. The data from this analysis is to be presented in ASH 2021. 

BOS or Bronchiolitis Obliterans Syndrome is an inflammatory condition affecting small air paths in the lungs, called bronchioles. With the progression of the disease, the airways become inflamed and damaged, causing blockage and scarring. Allogeneic HCT can be associated with mortality and morbidity, along with BOS, resulting from a lung transplant. The condition can sometimes lead to mortality and re-transplantation. 

Leave a Comment

Your email address will not be published.

*